Get the Stockscreener App
4.38
3.06%
0.13
After Hours:
4.39
0.010
+0.23%
Perspective Therapeutics Inc stock is traded at $4.38, with a volume of 769.99K.
It is up +3.06% in the last 24 hours and down -12.40% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$4.25
Open:
$4.25
24h Volume:
769.99K
Relative Volume:
0.24
Market Cap:
$499.03M
Revenue:
$884.00K
Net Income/Loss:
$-103.64M
P/E Ratio:
-3.1411
EPS:
-1.3944
Net Cash Flow:
$-95.45M
1W Performance:
+0.23%
1M Performance:
-12.40%
6M Performance:
-12.05%
1Y Performance:
+109.57%
1-Day Range:
$4.05
$4.39
1-Week Range:
$4.05
$4.53
52-Week Range:
$1.75
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
4.38 | 484.22M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Piper Sandler | Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-10-25 | Initiated | BTIG Research | Buy |
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics Inc. R (AAJ0.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
CATX Technical Analysis | Trend, Signals & Chart Patterns | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
CATX Stock Price, Quote & Chart | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
PERSPECTIVE THERAPEUTICS INC (CATX) Fundamental Analysis & Valuation - ChartMill
Perspective Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Perspective Therapeutics Advances First-in-Class 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective Therapeutics Highlights Progress in 212Pb Oncology Pipeline - TipRanks
Perspective Therapeutics updates corporate presentation, expects Phase 1/2 data across three programs in 2026 - TradingView — Track All Markets
Perspective Therapeutics (NYSE: CATX) spotlights 212Pb radiopharmaceutical cancer pipeline - Stock Titan
Revenue Check: Can Perspective Therapeutics Inc grow without dilution2026 Sentiment & Proven Capital Preservation Methods - baoquankhu1.vn
Analyst Upgrade: Can Perspective Therapeutics Inc expand into new marketsRisk Management & Weekly Hot Stock Watchlists - baoquankhu1.vn
Aug Analyst Calls: What is the next catalyst for Perspective Therapeutics IncGlobal Markets & Advanced Technical Analysis Signals - baoquankhu1.vn
Perspective Therapeutics Q1 EPS Raised by HC Wainwright - MarketBeat
Investment Recap: What is the next catalyst for Perspective Therapeutics IncMarket Growth Report & Risk Controlled Daily Plans - baoquankhu1.vn
H.C. Wainwright raises Perspective Therapeutics price target to $13 By Investing.com - Investing.com South Africa
CATX: HC Wainwright & Co. Raises Price Target to $13, Maintains Buy Rating | CATX Stock News - GuruFocus
H.C. Wainwright raises Perspective Therapeutics price target to $13 - Investing.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $13.00 Price Target at HC Wainwright - MarketBeat
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
If You Invested $1,000 in Perspective Therapeutics Inc (CATX) - Stock Titan
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
CATX Should I Buy - Intellectia AI
Perspective Therapeutics Q1 EPS Boosted by Brookline Cap M - MarketBeat
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Perspective Therapeutics (CATX) - The Globe and Mail
Jones Trading reiterates Perspective Therapeutics stock Buy rating By Investing.com - Investing.com India
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Jones Trading reiterates Perspective Therapeutics stock Buy rating - Investing.com
Perspective Therapeutics (CATX) Receives Analyst Rating Boost | CATX Stock News - GuruFocus
B. Riley Financial Issues Positive Forecast for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price - MarketBeat
Perspective Therapeutics (CATX) Receives Analyst Rating Boost | - GuruFocus
Perspective Therapeutics (CATX) Receives Boost from UBS with Rai - GuruFocus
Perspective Therapeutics price target raised to $13 from $11 at B. Riley - TipRanks
UBS Adjusts Price Target on Perspective Therapeutics to $8 From $7, Maintains Buy Rating - marketscreener.com
UBS Group Forecasts Strong Price Appreciation for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock - MarketBeat
Perspective Therapeutics (CATX) Rating Reiterated by Wedbush | C - GuruFocus
Perspective Therapeutics (NYSEAMERICAN:CATX) Receives Outperform Rating from Wedbush - MarketBeat
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT) - The Globe and Mail
B. Riley Raises Price Target on Perspective Therapeutics to $13 From $11, Keeps Buy Rating - marketscreener.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026 - The Manila Times
Perspective Therapeutics (CATX) to Release Earnings on Wednesday - MarketBeat
RBC cuts Perspective Therapeutics stock price target on model updates By Investing.com - Investing.com Australia
Perspective Therapeutics Q4 2025 earnings preview - MSN
Truist reiterates Buy on Perspective Therapeutics stock By Investing.com - Investing.com Canada
BTIG Reiterates Buy Rating for CATX with $14 Price Target | CATX Stock News - GuruFocus
Royal Bank Of Canada Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $14.00 - MarketBeat
RBC Capital Lowers Price Target for CATX While Maintaining 'Outp - GuruFocus
Truist reiterates Buy on Perspective Therapeutics stock - Investing.com
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
0.00%
Cap:
|
Volume (24h):